Objective: Immunosuppressive agents have been proposed to reduce neointimal hyperplasia in synthetic vascular grafts. Thus, the purpose of the present study was to evaluate the safety and ef®cacy of rapamycins (systemic vs. local vs. oral administration) and mycophenolate mofetil (MMF) to reduce intimal hyperplasia in infrarenal synthetic vascular grafts of the rat. Methods: Fifty-four Wistar rats (250 g) completed the study after a synthetic vascular graft (ePTFE, Gore-tex, 2 mm diameter, 10 mm length) was implanted end-to-end in the infrarenal aorta. The animals were divided into three groups: group 1 consisted of 12 control animals, group 2 consisted of 37 rats receiving rapamycins, either per os (RAD, 1.5 or 3 mg/kg), intraperitoneally (RPM, 1.5 or 3 mg/kg) or locally (RPM soaking of the graft); and in group 3 (n 5), MMF (40 mg/kg) was administered orally. The animals were followed weekly with weight controls and signs of toxicity for 30 (n 37) and 60 (n 17) days, respectively. All animals were sacri®ced and underwent histological examination at completion of the study. Results: All animals survived in groups 1 and 3, but ®ve died in group 2. The weight gain was normal in all groups, except for the subgroup 2a receiving high dose rapamycins orally. All rats in group 3 suffered from diarrhea, whereas animals receiving high dose rapamycins showed toxic signs (hair loss, wound healing problems). Histological examination showed a signi®cant increase in intimal hyperplasia in group 1 (0.03^0.01 and 0.14^0.05 mm after 30 and 60 days, respectively; P , 0:01). Rapamycins in either application or dosage had no signi®cant effect on intimal hyperplasia. Conclusions: Local or systemic administration of rapamycins has no effect on intimal hyperplasia in synthetic vascular grafts. In contrast, toxic signs with weight loss were observed in animals treated with high dose rapamycins, but not in those treated with MMF. Thus, in the rat model, immunosuppresssion with rapamycins or MMF cannot be recommended for the prevention of intimal hyperplasia in the synthetic vascular graft model. q
Introduction
Coronary and peripheral bypass operations are performed routinely for myocardial or peripheral ischemia. The best results are obtained with autologous arterial or venous graft materials, like internal mammary artery and saphenous vein grafts. However, graft material can be limited due to vein disease or previous use of vein material. Therefore, synthetic graft material has been used as a substitute, but vascular grafts below 6 mm diameter have a high occlusion rate, mainly due to graft thrombosis in the early phase and intimal hyperplasia in the late phase [1] . Early graft thrombosis can be minimized with good surgical techniques, and adequate antiplatelet or anticoagulation treatment in patients with a good run-off. More recently, new graft material and the surface (heparin) coating of grafts have been shown to improve graft patency [2] . However, graft occlusion due to intimal hyperplasia remains a major problem. Several methods have been used to improve graft patency in small vascular grafts, such as pharmacological interventions, cell seeding and, more recently, tissue engineering of synthetic grafts [3] . Immunosuppressive agents have been used only rarely due to unwanted side-effects, but the antiproliferative properties may reduce intimal hyperplasia [4±6]. Gregory and co-workers have shown that a high dose of rapamycins reduces intimal hyperplasia in the rat carotid artery injury model [7, 8] 
Materials and methods
In 69 Wistar rats, an infrarenal interposition expanded polytetra¯uoroethylene (ePTFE; Gore-tex) graft was implanted under general anesthesia using intraperitoneal uanisone (Janssen-Cilag). The operations were performed through a midline total laparotomy using sterile and microsurgical techniques. After preparation of the infrarenal aorta, clamping, resection and end-to-end single stitch (10.0 mono®lament), implantation was performed. The thin-walled, Gore-tex graft had an internal diameter of 2 mm and a length of 10 mm. The graft patency was tested manually and the laparotomy was closed in two layers. Postoperatively, no antiplatelet drugs or heparin therapy were given. All animals had standard care and received normal food.
The animals were divided into three groups: control group 1 (n 12), group 2 treated with rapamycins (n 37), and group 3 treated with MMF (n 5). Group 2 was further subdivided according to the route of administration and the dosage: 2a rapamycins (RAD Novartis 1.5 or 3 mg/kg per os by gavage). 2b rapamycins (RPM Wyeth 1.5 or 3 mg/kg intraperitoneally). 2c rapamycin graft soaking (RPM Wyeth).
In the last group, the grafts were immersed for 24 h in a rapamycin saline solution on an agitator at room temperature. The animals were followed daily for graft occlusion and drug toxicity. Body weight was measured weekly.
Each group was scheduled to comprise six animals. Four animals died perioperatively, of narcosis accident (two) and perioperative bleeding (two), and one animal in the treatment group was inadvertently placed in the long-term control group (n 7). All of those four animals were replaced. In addition, ®ve animals had to be euthanized during the ®rst 2 weeks. Two for graft thrombosis and hind leg ischemia, and three for wound problems (poor healing and secondary dehiscence). These animals were also replaced. Thus, a total of 69 rats were operated.
At the conclusion of the study, either after 30 or 60 days, the animals were anesthetized and euthanized by potassium chloride overdose, and the grafts were dissected free and pressure perfused in situ with glutalaldehyde. The grafts were cut longitudinally, and after hematoxylin and eosin staining, sections were examined at the proximal and distal anastomoses, as well as in the middle of the graft according to the following criteria: graft patency dimensions and intimal proliferation thickness, length and area, as well as a grading score (0, none; 1, mild; 2, moderate; and 3, severe) for intimal proliferation, thrombus formation and cellular ingrowth. The scores were given by an experienced vascular pathologist blinded to the treatment groups.
All animals received human care in compliance with the European Convention on Animal Care. The study was approved by the veterinary ethical committee.
Statistics
The results are expressed as mean values^1 SEM for ®gures or mean values^1 SD for tables, respectively. Differences between proximal and distal anastomoses were calculated using the paired t-test. Differences among the three groups were evaluated with a one-way analysis of variance (ANOVA). When the analysis was signi®cant, a Kruskal±Wallis test was performed. Comparisons within the same group were carried out with an ANOVA for repeated measurements (Mann±Whitney Test with Bonferroni correction) using the STATA software (Santa Monica, USA).
Results

Survival, body weight and side-effects
Except for the four animals dying perioperatively and the ®ve animals who were euthanized during the ®rst 2 weeks (see above), all other animals had an uneventful recovery after the intervention.
During the follow-up, no animal died in group 1. Five animals died in group 2, four probably related to drug toxicity (oral RAD) and one from late thrombosis (rapamycin treated graft). In group 3, one animal was euthanized because of severe diarrhea. Thus, 54 animals completed the study.
After 3 weeks of treatment, most animals in group 2, mainly the ones treated with oral or high dose rapamycins, developed signs of toxicity. These included appetite and weight loss, diarrhea, hair loss, aggressivity and wound dehiscences (Table 1) .
Rats in the control group showed an increase in body weight of about 150 g during the ®rst month and about an equal amount during the second month. The animals of group 2c (rapamycin graft soaking) and group 3 (MMF) showed a similar weight increase than the control group animals. In contrast, especially the animals of group 2a (RAD) receiving the high dosage, showed a signi®cantly lower weight increase at 30 and 60 days, respectively when compared with controls (Table 1 ; Fig. 1A,B) . Fig. 2A,B) Intimal hyperplasia thickness was present at both anasto-moses and similar in groups 1 and 2 after 30 days. The animals of group 3 showed a higher intimal proliferation compared with the animals treated systemically with rapamycins (0.06^0.02 vs. 0.02^0.01; P , 0:01). There was a signi®cant increase in the controls from 30 to 60 days (0.03^0.01 vs. 0.14^0.05 mm; P , 0:01). In group 2, there were some differences with regard to the mode of rapamycin application and dosage, i.e. there was a trend towards a lower intimal proliferation in animals receiving systemic RAD per os, especially in the high dosage. Animals treated with the high dosage RAD per os showed a signi®cantly lower intimal thickening when compared with control animals at 2 months (0.04^0.02 vs. 0.1^0.08; P , 0:05). In contrast, the animals of group 2c (RPM graft soaking) showed no bene®cial effect on intimal proliferation. After 2 months, the animals had a similar intimal proliferation to the controls. Intimal hyperplasia was more pronounced at the proximal anastomosis, followed by the distal anastomosis and the middle of the prosthesis (Table 2 ; Fig. 3A,B) .
Histological evaluation (
Intimal hyperplasia, thrombus formation and cellular ingrowth scores were assessed by using a score from 0 to 3 (0, none; 3, severe). The results of the intimal hyperplasia score were similar to the measured intimal hyperplasia thicknesses (Table 2 ). There was a trend towards more thrombus formation on the inner surface of the graft in the animals of group 2a which were treated with oral RAD. In addition, grafts treated with rapamycins induced more thrombus formation (group 2c; Fig. 4A,B) . Cellular ingrowth was similar to intimal hyperplasia formation and showed some trend towards a lesser cellular ingrowth in animals with high dose immunosuppression.
Discussion
Intimal hyperplasia and graft occlusion are the major limitations for small caliber synthetic vascular grafts. Therefore, veins and, more recently, arteries have been Group 2c (RPM soaking) shows a similar weight increase as the controls up to 1 month. Group 2b (RPM) has a normal weight increase at 1 month, whereas group 2a (RAD) shows a signi®cantly reduced weight increase at 30 (P 0:01) and 60 days (P 0:005). used for cardiovascular bypass surgery, but a limited availability of graft material has led to the use of complex anastomoses in bypass techniques, such as the use of gastroepiploic, radial and mammary arteries. The need for synthetic graft material for small bypass grafts is increasing dramatically, especially for the second or third bypass operation or for patients with inadequate autologous graft material. The purpose of the present study was to assess the effect of immunosuppressive drugs for the prevention of neointimal hyperplasia in small vascular synthetic grafts. The results were assessed at 30 and 60 days, since it has been shown in rat models that the strongest mediator and growth-factor activity happens during the ®rst 2±3 weeks [13] .
Intimal proliferation increased with time and was more pronounced at the anastomoses than in the center of the synthetic vascular grafts (Table 2) . Rapamycin treated grafts showed less intimal proliferation than control grafts (.0.05), but due to the large variations, this difference did not reach statistical signi®cance. No effect was seen with MFF treated rats when compared with controls (Fig. 3A) . Due to the high dose, rapamycins were associated with weight loss and signs of toxicity (diarrhea, loss of hair and wound healing problems). However, no clear effect on patency was found. There was an increased thrombus formation, especially in the high dose rapamycin groups (P , 0:01; Fig. 4B ). This is probably due to the diminished endothelialization provoked by the high dose of immunosuppression [14±16].
In conclusion, high dose immunosuppression reduces mildly intimal proliferation, especially at the anastomosis in synthetic vascular grafts in the rat. This bene®cial effect is linked with increased drug toxicity. Thus, these side-effects and the lack of a signi®cant reduction in intimal hyperplasia limit the use of systemically administered immunosuppressive drugs for the prevention of intimal hyperplasia and graft occlusion in small caliber synthetic vascular grafts. Fig. 4 . Thrombus formation score (0±3: 0, none; 3, severe). (A) Animals of group 2 show a markedly higher thrombus formation score than the control animals. (B) There is a signi®cant increase of thrombus formation on rapamycin treated grafts (RPM soaking; group 2c) compared with low dose rapamycins, and a signi®cant increase in animals treated with high dose rapamycins (group 2a; P 0:01).
